Looks like you’re on the UK site. Choose another location to see content specific to your location
Dechra makes Spiromune available for feline chronic allergic dermatitis
Dechra has announced that its atopic dermatitis therapy Spiromune is being made available for use in cats.
The solution has been licensed for the symptomatic treatment of chronic allergic dermatitis in cats, making it the first ciclosporin oral solution to be licensed for use in both cats and dogs.
It has proven to be an effective alternative to prednisolone, with a positive long-term safety record among canine users, and is now considered among the most important tools within a multimodal treatment strategy.
Sporimune is available with two dosing syringes per bottle, one for cats and one for dogs, with its liquid formulation ensuring it can be easily titrated to account for the animal's weight.
Claire Morgan, Dechra's brand manager, said: "Sporimune is a key component of a multimodal approach involving guidance on allergen and flare factor avoidance and improving skin and coat hygiene to minimise clinical signs and the effects on quality of life."
Allergic skin disease can be challenging to diagnose and manage effectively, with around 20 per cent of all small animal consultations involving skin conditions. The expansion of Spiromune's licence will increase its utility in tackling these problems.
With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard